Choosing the right respiratory CRO (Contract Research Organisation) can be an important decision for pharmaceutical and biotechnology companies developing new treatments for respiratory disease.
Preclinical respiratory research involves more than selecting an experimental model and measuring a response. Research teams need to consider the biological mechanism, suitability of the disease model, selection of endpoints, interpretation of results and relevance to the wider drug development programme.
For companies developing treatments for asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, acute lung injury or respiratory infections, selecting an appropriate research partner can help address these scientific challenges.
A specialist respiratory CRO may provide support across respiratory pharmacology, disease modelling, in vivo studies and preclinical efficacy testing. However, capabilities differ between providers, and the most suitable partner will depend on the specific objectives of the research programme.
The key is to evaluate a respiratory CRO based on its ability to answer your scientific questions, not simply the number of services listed on its website.
This guide explains what to look for when selecting a respiratory research partner, which questions to ask before starting a study, and how to assess whether a CRO’s capabilities align with your drug development objectives.
What Is a Respiratory CRO?
A respiratory CRO provides contract research services to organisations investigating respiratory diseases and developing potential respiratory therapeutics.
Depending on its expertise, a respiratory research organisation may support early discovery, preclinical pharmacology, disease-model development and experimental efficacy studies.
These services can be relevant to companies working on:
- Asthma drug development
- COPD drug development
- Pulmonary fibrosis research
- Acute lung injury and acute respiratory distress syndrome (ARDS)
- Respiratory inflammation
- Viral respiratory disease
- Airway hyperresponsiveness
- Inhaled drug development
- Novel pulmonary therapeutics
A respiratory CRO may also help research teams investigate the biological mechanisms underlying disease and determine whether a candidate produces a measurable pharmacological response.
Not every CRO provides the same capabilities. Some focus on general toxicology or broad preclinical services, while others specialise in particular respiratory indications, experimental models or pharmacological approaches.
Understanding this distinction is an important first step when evaluating potential research partners.
1. Evaluate the CRO’s Respiratory Disease Model Expertise
One of the first considerations when choosing a respiratory CRO is its experience with the disease biology relevant to your therapeutic candidate.
Respiratory diseases involve different biological mechanisms, and no single experimental model can adequately represent every aspect of every disease.
For example, asthma research may investigate airway inflammation, immune responses and airway hyperresponsiveness. COPD research may focus on chronic inflammation, structural changes and emphysema-related pathology. Pulmonary fibrosis research requires approaches suited to studying fibrotic processes and tissue remodelling.
A CRO should be able to explain why a particular model is appropriate for the research question.
Questions to ask include:
- Which respiratory disease models are available?
- What biological features does each model reproduce?
- Which aspects of the human disease does the model not represent?
- Which endpoints can be measured?
- How will the model help answer the study’s primary question?
- What limitations should be considered when interpreting the results?
These questions help establish whether the proposed research is scientifically appropriate.
A model that is suitable for demonstrating activity against one biological pathway may be less informative for a candidate targeting another mechanism. Model selection should therefore be driven by the therapeutic hypothesis rather than convenience alone.
2. Look for Relevant Respiratory Pharmacology Experience
Respiratory pharmacology examines how potential therapeutics interact with biological systems involved in respiratory disease.
When selecting a respiratory CRO, it is worth investigating whether its capabilities align with the mechanism of action of your drug candidate.
Relevant areas may include:
- Anti-inflammatory pharmacology
- Airway smooth muscle activity
- Airway hyperresponsiveness
- Immune signalling
- Pulmonary inflammation
- Fibrotic pathways
- Respiratory infection
- Pharmacodynamic biomarker analysis
A research partner with relevant pharmacology experience may be better placed to help select meaningful endpoints and interpret experimental findings in context.
For example, a company developing an anti-inflammatory asthma treatment may need evidence that its candidate affects a particular inflammatory pathway. A programme investigating a potential anti-fibrotic treatment may require measurements relating to fibrotic activity and tissue remodelling.
The experimental strategy should reflect these differences.
When evaluating a respiratory CRO, ask how the proposed studies connect the candidate’s mechanism of action with the expected biological response.
3. Assess the CRO’s Preclinical Efficacy Testing Capabilities
Preclinical efficacy testing helps determine whether a therapeutic candidate produces a measurable effect in an appropriate experimental system.
However, the usefulness of a study depends on how well its design addresses the development question.
Before commissioning a study, consider whether the CRO can explain:
- The primary efficacy endpoint
- The rationale for selecting that endpoint
- The proposed control groups
- The approach to dose selection
- The timing of measurements
- The planned statistical analysis
- The criteria for interpreting the results
A clearly defined primary endpoint is particularly important. Without one, a study can generate a large amount of data without providing a decisive answer to the original research question.
Secondary endpoints can add useful context, but they should complement rather than obscure the primary objective.
A prospective research partner should also explain how experimental variability will be managed and how the limitations of the chosen model may influence interpretation.
For companies progressing a candidate towards proof of concept, these considerations can help make preclinical efficacy studies more informative for subsequent development decisions.
4. Understand the CRO’s In Vivo Respiratory Research Capabilities
In vivo respiratory studies can provide information about biological responses within an intact organism.
Depending on the indication and research objectives, studies may investigate inflammation, airway responses, tissue pathology, pharmacological activity or other disease-associated endpoints.
When assessing a respiratory CRO, consider its experience with the particular techniques and measurements required for your programme.
For example, a study may require:
- Respiratory disease induction and assessment
- Measurement of airway responsiveness
- Collection and analysis of biological samples
- Pulmonary histopathology
- Inflammatory cell analysis
- Biomarker measurements
- Dose-response assessment
- Integration of pharmacological and pathological findings
The important question is not simply whether a CRO conducts in vivo studies. It is whether it has the appropriate capabilities to execute the proposed experimental design reliably.
It is also useful to understand how the CRO manages study quality, documentation, data review and reporting.
These practical considerations can affect how confidently a research team can interpret and use the resulting data.
5. Consider Pharmacokinetics and Pharmacodynamics
Pharmacokinetic (PK) and pharmacodynamic (PD) data can help explain the relationship between drug exposure and biological response.
Pharmacokinetics examines how a candidate is absorbed, distributed, metabolised and eliminated. Pharmacodynamics investigates the effects produced by the candidate.
For respiratory drug development, these measurements can be particularly relevant when researchers need to establish whether a compound reaches the relevant tissues and produces the expected pharmacological effect.
A research programme may therefore benefit from considering:
- Drug exposure over time
- Dose-response relationships
- Target engagement
- Pharmacodynamic biomarkers
- Duration of biological activity
- Local and systemic exposure
- Relationships between exposure and efficacy
Not every respiratory CRO provides comprehensive PK/PD services internally. Where these capabilities are required, companies should clarify whether they are available directly, delivered through a partner or outside the proposed scope.
The objective is to ensure that the study can generate the evidence needed to interpret the candidate’s activity, rather than measuring efficacy without understanding the exposure associated with the response.
6. Look for Relevant Biomarker Expertise
Respiratory biomarkers can provide measurable evidence of biological processes associated with disease or treatment.
Depending on the therapeutic programme, biomarkers may help investigate inflammation, immune activation, tissue injury, fibrotic activity or target engagement.
When assessing a respiratory CRO, ask whether it can support the biomarker strategy required for your candidate.
Important considerations include:
- Whether the biomarker is relevant to the proposed mechanism
- Whether the measurement method is appropriate
- How samples will be collected and handled
- Whether the assay is sufficiently characterised for its intended use
- How biomarker findings will be interpreted alongside efficacy data
Biomarkers can be especially useful when a candidate is expected to affect a specific biological pathway before changes in broader disease outcomes become apparent.
However, a change in a biomarker does not automatically demonstrate clinical benefit. Its meaning depends on the biological context and the evidence supporting its interpretation.
A CRO should be able to explain how biomarker results contribute to the overall research question.
7. Evaluate the CRO’s Translational Research Approach
Translational respiratory research aims to connect preclinical findings with the biology and measurements relevant to human disease.
This is an important consideration because experimental models cannot reproduce every aspect of human respiratory disease.
A translational approach should consider which findings are likely to be informative for clinical development and which uncertainties remain.
When evaluating a research partner, ask:
- How does the proposed model relate to the intended patient population?
- Are the selected endpoints relevant to the therapeutic mechanism?
- Can biomarkers be investigated in both preclinical and clinical settings?
- What limitations might affect translation?
- How will the results inform the next development decision?
For example, if a drug candidate is intended to modify a specific inflammatory pathway in asthma, it may be useful to understand both the response observed in the model and the evidence connecting that pathway with human disease.
A good translational strategy does not promise that preclinical results will predict clinical success. Instead, it aims to make those results more interpretable and relevant to subsequent decisions.
8. Check Study Design, Reporting and Data Quality
Scientific expertise is only one part of choosing a respiratory CRO. The quality of study design, execution and reporting is equally important.
Before a study begins, the research team should understand the proposed protocol and how the resulting data will be documented.
Consider asking about:
- Study protocols and approval processes
- Appropriate randomisation and blinding
- Sample-size rationale
- Inclusion and exclusion criteria
- Handling of missing or unexpected data
- Statistical analysis plans
- Raw data access
- Final report structure
- Documentation and quality systems
The level of formality required will depend on the purpose of the study.
Exploratory research may have different requirements from studies intended to contribute to a regulatory submission. Where regulated work is needed, confirm the CRO’s relevant experience and the specific standards applicable to the programme.
Clear reporting is particularly valuable when results will be reviewed by internal discovery teams, external collaborators or development decision-makers.
9. Assess Communication and Scientific Collaboration
Preclinical respiratory research often involves decisions that evolve as new findings emerge.
A research partner should be able to communicate clearly about the study’s objectives, progress, limitations and results.
Before selecting a CRO, establish how the collaboration will work in practice.
Useful questions include:
- Who will be the scientific point of contact?
- How frequently will progress be communicated?
- How will unexpected findings be discussed?
- What happens if the original study design needs to be reconsidered?
- How will protocol changes be approved?
- How will the final results be presented and discussed?
Scientific collaboration is particularly important when the study involves a novel mechanism or an experimental model with recognised limitations.
The ability to discuss results critically can be more valuable than simply receiving a report containing positive or negative findings.
10. Match the CRO to Your Stage of Drug Development
The right respiratory research partner also depends on where the candidate sits within the development process.
Early discovery
At the discovery stage, the priority may be understanding the biological target, evaluating candidate activity and investigating mechanism.
A suitable research partner may need to support exploratory respiratory pharmacology and early experimental screening.
Preclinical efficacy and proof of concept
At this stage, the objective may be to determine whether the candidate produces a meaningful response in a relevant disease model.
Research capabilities may include disease modelling, dose-response assessment, biomarker analysis and in vivo efficacy studies.
Advanced preclinical development
As a programme progresses, the research questions may increasingly involve exposure-response relationships, safety, reproducibility and evidence needed to support further development.
The required package will depend on the therapeutic candidate and intended development pathway. Not every CRO is equipped to support every stage.
Clearly defining the next decision your research needs to support can help identify the most appropriate partner and prevent unnecessary studies.
Questions to Ask Before Selecting a Respiratory CRO
Use this checklist when comparing potential respiratory research providers.
- Does the CRO have experience relevant to our respiratory indication?
- Can it explain why the proposed disease model is appropriate?
- Does it understand our candidate’s mechanism of action?
- Are the proposed endpoints aligned with our research objectives?
- Can it support the required in vivo studies and biomarker measurements?
- Are PK/PD capabilities available if needed?
- Are study quality, data access and reporting arrangements clear?
- Can the research programme support our next development decision?
- Are the limitations and uncertainties of the proposed approach explained?
- Is there a clear plan for communication and scientific review?
These questions provide a practical starting point for evaluating whether a CRO can meet the scientific requirements of a respiratory drug development programme.
Why Specialist Respiratory Research Matters
Respiratory drug development spans a wide range of disease mechanisms, experimental models and therapeutic approaches.
A study designed for airway inflammation may not answer the same questions as one investigating pulmonary fibrosis or respiratory infection. Similarly, a candidate with a novel mechanism may require a more tailored pharmacology strategy than a well-characterised compound.
Working with a research organisation that understands the relevant respiratory biology can help ensure that experimental models, endpoints and study objectives are aligned.
For pharmaceutical and biotechnology companies, the value of a respiratory CRO should therefore be assessed in terms of the scientific questions it can address, the quality of the evidence it can generate and the relevance of that evidence to the next stage of development.
Respiratory CRO Services at Virtus Respiratory Research
Virtus Respiratory Research works within the field of respiratory research. For organisations exploring external research support, the appropriate starting point is to define the respiratory indication, therapeutic mechanism and preclinical question that needs to be answered.
These details help establish which research capabilities, disease models and endpoints are relevant to a potential project.
When evaluating a respiratory research programme, it is useful to discuss:
- The respiratory disease or biological pathway being investigated
- The stage of drug development
- The candidate’s proposed mechanism of action
- The desired pharmacological or efficacy endpoints
- Any biomarker or translational objectives
- The evidence required to support the next development decision
If you are evaluating a respiratory CRO for an upcoming preclinical study, contact Virtus Respiratory Research to discuss your research objectives and determine whether its capabilities are appropriate for your programme.
Conclusion
Choosing a respiratory CRO is an important decision for companies developing new respiratory therapeutics.
The most suitable research partner will depend on the disease indication, therapeutic mechanism, development stage and specific evidence required from the study.
By evaluating respiratory disease model expertise, pharmacology, in vivo research capabilities, biomarkers, PK/PD, study quality and scientific collaboration, companies can make a more informed assessment of potential providers.
Ultimately, effective respiratory preclinical research should do more than generate experimental data. It should help researchers understand the candidate’s biological activity, identify important uncertainties and make better-informed decisions about further development.
A carefully selected respiratory CRO can contribute to that process by aligning experimental design, respiratory biology and preclinical evidence with the needs of the drug development programme.